Aprea Therapeutics, Inc. (APRE) is listed on NASDAQ in the Manufacturing sector. This page tracks real-time APRE price, technical indicators including RSI, MACD, and the 52-week range, plus fundamentals, earnings history, and recent insider trading activity.
Technical Analysis
RSI (14) 47.3 Neutral
Market Cap $8.2M
Volume 9.9K
Fundamentals — 10-Q Q1 2026
Revenue --
Net Income $-3.3M
EPS $-0.22
P/E Ratio -3.0x
Earnings
Recent Insider Trades
| Name | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | 5,000 | $1.17 | $5,850 | 2025 Dec 10 |
| Duey Marc | Director | Buy | 21,459 | $1.17 | $25,107 | 2025 Dec 10 |
| Gilad Oren | President/CEO | Buy | 5,500 | $1.84 | $10,110 | 2025 Apr 3 |
| Gilad Oren | President/CEO | Buy | 500 | $3.92 | $1,960 | 2024 Oct 23 |
| Duey Marc | Director | Sell | 6,462 | $4.58 | $29,596 | 2024 Oct 18 |
| Duey Marc | Director | Buy | 30,000 | $4.39 | $131,700 | 2024 Oct 16 |
| Gilad Oren | President/CEO | Buy | 250 | $2.90 | $725 | 2024 Oct 15 |
| Duey Marc | Director | Buy | 190 | $2.58 | $490 | 2024 Oct 14 |
| Gilad Oren | President/CEO | Buy | 1,150 | $2.58 | $2,971 | 2024 Oct 14 |
| Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | 50 | $2.46 | $123 | 2024 Oct 11 |
| Seizinger Bernd R. | Director | Buy | 10,000 | $2.68 | $26,800 | 2024 Oct 11 |
| Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | 450 | $2.61 | $1,175 | 2024 Oct 10 |
| Henneman John B III | Director | Buy | 6,860 | $7.29 | $50,009 | 2024 Mar 13 |
| Seizinger Bernd R. | Director | Buy | 6,860 | $7.29 | $50,009 | 2024 Mar 13 |
| Gilad Oren | President, CEO | Buy | 2,000 | $7.29 | $14,580 | 2024 Mar 13 |
| Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | 1,010 | $7.29 | $7,363 | 2024 Mar 13 |
| Seizinger Bernd R. | Director | Buy | 10,097 | $3.66 | $36,954 | 2023 Jun 7 |
| Seizinger Bernd R. | Director | Buy | 50,000 | $0.71 | $35,500 | 2022 May 18 |
| Schade Christian S | Chairman & CEO | Buy | 37,500 | $0.64 | $24,000 | 2022 May 18 |
| Attar Eyal C. | SVP, Chief Medical Officer | Sell | 36,000 | $1.73 | $62,280 | 2022 Feb 28 |
Take APRE further
- Browse Pharmaceutical Stocks for the rest of the group, with what the businesses in it have in common and where they differ.
- Put APRE in a portfolio and see what it does to total return, drawdown, and how the rest of your holdings move with it. Compares against the S&P 500 over the same days, free and without an account.
- Screen for others like it by RSI, valuation, market cap, and insider activity.
- Check the earnings calendar for when Aprea Therapeutics, Inc. next reports.
Set alerts on APRE
Get notified when Aprea Therapeutics, Inc. hits your price targets or technical conditions are met.
Get Started Free